Drug intelligence / Profile preview

Acenewrax

Development stage: Unknown
Lead developer: ARAX Pharmaceutical Industries
Modality: Small Molecules
Administration: Oral

Overview

Acenewrax is a mucolytic medication containing acetylcysteine, developed and marketed by ARAX Pharmaceutical Industries in Egypt. It is primarily indicated for the treatment of respiratory conditions characterized by thick, viscous mucus, such as acute bronchial diseases. The drug's mechanism of action involves its free sulfhydryl group, which chemically reduces the disulfide bonds within the mucus glycoprotein matrix, thereby decreasing mucus viscosity and facilitating expectoration. Acenewrax is available in oral formulations, specifically 200mg and 600mg effervescent sachets. Additionally, the active ingredient acetylcysteine is recognized for its roles as an antidote for paracetamol toxicity and a prophylactic against contrast-induced nephropathy.

Brand names: Acenewrax

Targets

MUC2 (Mucin-2)

Beyond the preview

Go deeper on Acenewrax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acenewrax.

Explore the full profile